- Absences from work of employed full-time wage and salary workers by occupation and industry. (2018). Available at: https://www.bls.gov/cps/cpsaat47.htm#cps_eeann_abs_ft_occu_ind.f.1. (Accessed: 17th September 2018)
- Rebecca J. Mitchell, P. B. Measuring Health-Related Productivity Loss. Popul. Health Manag. 14, 93 (2011).
- Finch, R. & Phillips, K. An Employer’s Guide to Behavioral Health Services: A Roadmap and Recommendations for Evaluating, Designing, and Implementing Behavioral Health Services. (National Business Group on Health, 2005).
- Alper, B. S., Hand, J. A., Elliott, S. G., Kinkade, S., Hauan, M. J., Onion, D. K., & Sklar, B. M. (2004). How much effort is needed to keep up with the literature relevant for primary care?. Journal of the Medical Library association, 92(4), 429.
- (2018). Available at: https://www.cdc.gov/nchs/fastats/drug-use-therapeutic.htm. (Accessed: 17th August 2018)
- Parekh, A. K., Goodman, R. A., Gordon, C., Koh, H. K., & HHS Interagency Workgroup on Multiple Chronic Conditions. (2011). Managing multiple chronic conditions: a strategic framework for improving health outcomes and quality of life. Public health reports, 126(4), 460-471.4
- Anderson, G. (2010) Chronic Care: Making the Case for Ongoing Care. Robert Wood Johnson Foundation.
- Chronic Disease Prevention and Health Promotion. (2018) Center for Disease Control and Prevention CDC . Available at: https://www.cdc.gov/chronicdisease/about/index.htm. (Accessed: 17th August 2018)
- Gerteis, J., Izrael, D., Deitz, D., LeRoy, L., Ricciardi, R., Miller, T., & Basu, J. (2014). Multiple chronic conditions chartbook. Rockville, MD: Agency for Healthcare Research and Quality.
- Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200–1205 (1998).
- Center for Education and Research on Therapeutics. FDA Adverse Drug Reaction (ADR) learning module. Preventable Adverse Drug Reactions: A Focus on Drug Interactions Available at: https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm110632.htm. (Accessed: 2nd August 2018)
- Lavan, A. H. & Gallagher, P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf 7, 11–22 (2016).
- Budnitz, Daniel S., Daniel A. Pollock, Kelly N. Weidenbach, Aaron B. Mendelsohn, Thomas J. Schroeder, and Joseph L. Annest. “National Surveillance of Emergency Department Visits for Outpatient Adverse Drug Events.” JAMA 296, no. 15 (October 18, 2006): 1858–66. https://doi.org/10.1001/jama.296.15.1858.
- Kongkaew C, Hann M, Mandal J, Williams SD, Metcalfe D, Noyce PR, Ashcroft DM. Risk factors for hospital admissions associated with adverse drug events. – PubMed – NCBI.
- Ross Baker, G. et al. The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. CMAJ 170, 1678–1686 (2004).
- White, T. & Arakelian, A. Counting the costs of drug-related adverse events. Pharmacoeconomics 15, 445–458 (1999).
- Spear, B. B., Heath-Chiozzi, M. & Huff, J. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201–204 (2001).
- Baicker, K., Cutler, D., & Song, Z. (2010). Workplace wellness programs can generate savings. Health affairs, 29(2), 304-311.
- Arbogast, J. W., Moore-Schiltz, L., Jarvis, W. R., Harpster-Hagen, A., Hughes, J., & Parker, A. Impact of a comprehensive workplace hand hygiene program on employer health care insurance claims and costs, absenteeism, and employee perceptions and practices. Journal of occupational and environmental medicine, 58(6), e231 (2016).
- Wang, L., McLeod, H. L., & Weinshilboum, R. M.Genomics and drug response. New England Journal of Medicine, 364(12), 1144-1153 (2011).
- Winner, J., Allen, J. D., Altar, C. A. & Spahic-Mihajlovic, A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl. Psychiatry 3, e242 (2013).